Potential models were used for interaction studies with hypoxia-specific molecules (tirapazamine, apaziquone, and ENMD) using docking analysis. It also elucidates that the therapeutic effect is altered concerning population-dependent genetic changes in the individual. The study, therefore, asserts the need to set up a personalized drug design approach to enhance tumor hypoxia treatment efficacy.